Atossa Genetics

Atossa Genetics NASDAQ: ATOS is a Seattle-based healthcare firm that specializes in breast health.[1][2][3][4] The company focuses on the development and marketing of pharmaceuticals for the treatment of breast conditions, including breast cancer.[1][2][3][4]

Atossa Genetics
Public
Traded asNASDAQ: ATOS
IndustryBiotechnology
Founded2009
FounderDr. Steven Quay
HeadquartersSeattle, Washington
Key people
Dr. Steven Quay (CEO)
ProductsBreast Cancer Pharmaceuticals
Websitewww.atossagenetics.com

The company is named after the Persian Queen Atossa, who became the first woman in recorded history with breast cancer around 470 B.C.[1][2][5][6]

History

In 2000, Dr. Steven Quay, a physician specializing in biological chemistry, invented a preventative screening method to identify precursors to breast cancer and to treat precancerous lesions.[1][2][4][6] In May 2016, Dr. Quay and Dr. Shu-Chih Chen, Ph.D. had published the book, "Nipple Aspirate Fluid Exfoliative Cytopathology and Molecular Biomarkers: Current Role in the Management of Breast Health," which describes the status of research and clinical practice involving the Atossa technology.

Quay founded Atossa Genetics in 2009.[7] The company went public and became listed on the NASDAQ stock exchange under the symbol ATOS in 2012.[8] In January 2013, Atossa launched the ForeCYTE Breast Health Test system. Atossa voluntarily recalled the system following an FDA warning letter that stated it needed additional FDA clearance due to changes made to the system following the FDA's prior approval.[9]

Atossa Genetics is sponsoring a Phase 2 clinical trial,[10] on the use of fulvestrant administered through a microcatheter into the lactiferous duct as neoadjuvant treatment for ductal carcinoma in situ and invasive breast cancer.

gollark: > oform.<|endoftext|>I'll try upgrading the next version, I'll have to switch to a better version.<|endoftext|>It's a shame I could switch a CC BIOS, but that's very irritating.<|endoftext|>I see. If you're running the commands directly into the sandbox, it will use a lot of logic.<|endoftext|>Well, yes, I did.<|endoftext|>Oh, you said that, and didn't do anything?<|endoftext|>But it's still running now.<|endoftext|>I have no clue what the "beware" means, because it's not really `gps`.<|endoftext|>No, the CLI is not an example.<|endoftext|>It also does random stuff, it's not helpful.<|endoftext|>It's not like it goes through your sandbox.<|endoftext|>I see.<|endoftext|>It's not like a program.<|endoftext|>Well, yes, for that.<|endoftext|>It's not really much easier to program.<|endoftext|>
gollark: So it'll be done with the 10 kilosteps I initially configured soon; I guess I'll run another 16000 or so, which should take about 3 hours.
gollark: The incredible march of technology.
gollark: (ping was in the output, blame the ineffable machinations of it)
gollark: > to have some sort of extremely powerful thing.<|endoftext|><@!341618941317349376> Are you meant to be "regular" or "regular" or something, instead of "subsidies"?<|endoftext|>Also, it seems to have been increasingly disconnected from the whole system.<|endoftext|>It seems like just saying that in the sense of "don't know how to make it", which has fallen out a lot of the time (most of which are not necessarily doing anything) and not having some sort of weird interaction which seems to have fallen out in my eyes when it's not necessary, and which I actually can't actually do anything about it for really long term calls, which need some sort of weird thing.<|endoftext|>So, I have a bunch of cases for different kinds of things, and some of the "smart" lights (with some sort of weird thing where you can't have one) and a bunch of cases for really weird reason.<|endoftext|>I think one of the most deeply nested ones seems to just be some sort of weird interaction between what happened to some network, and to some extent that some of the people involved

References

  1. "Overview". Atossa Genetics. Archived from the original on 1 February 2014. Retrieved 18 June 2014.
  2. "Atossa Genetics Inc (ATOS) IPO". NASDAQ. Retrieved 18 June 2014.
  3. "Atossa Genetics completes $6.6M financing round". FinSMEs. 27 June 2011. Retrieved 18 June 2014.
  4. "Atossa Genetics Inc". The New York Times. Retrieved 18 June 2014.
  5. Beth Potter (5 August 2011). "Atossa gearing up to sell breast-cancer detection device". Puget Sound Business Journal. Retrieved 18 June 2014.
  6. "Atossa Genetics Inc". Securities & Exchange Commission. 3 October 2012. Retrieved 18 June 2014.
  7. Luke Timmerman (21 May 2010). "Who Needs VCs? Steven Quay's Atossa Genetics Seeks Fast IPO For Breast Cancer Test". Xconomy. Retrieved 18 June 2014.
  8. Drew DeSilver (8 November 2012). "Seattle's Atossa Genetics completes pint-size IPO". The Seattle Times. Retrieved 18 June 2014.
  9. "Atossa recalls breast health device, shares tumble". Reuters. 4 October 2013. Retrieved 18 June 2014.
  10. "PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy". Clinicaltrials.gov. 28 August 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.